Puzzled by efficacy rates of approved COVID-19 vaccines ranging from 95% to 45%, Abhijith Anand, assistant professor in the Sam M. Walton College of Business, and Rajeev Sharma, professor at the University of Waikato in New Zealand, wondered if the prevalence of COVID-19 infection rates at the locations where pharmaceutical companies conducted trials might have had something to do with the differences in observed efficacies.

The researchers based their hunch on the fact that higher infection rates generally imply more mutant strains, which are likely to lead to more breakthrough infections and, consequently, reduce the efficacy of the vaccines observed in the trial.

"A lot of important decisions were being made by legislators, politicians and even the general public based on the reported vaccine efficacy numbers," said Anand. "The reported vaccine efficacy numbers varied a lot across different vaccines. We were interested in why there was a disparity."

Using data from the World Health Organization, McGill University, London School of Hygiene & Tropical Medicine Vaccine Centre, scientific publications,clinicaltrails.govand others, Anand and Sharma tracked the pharmaceutical companies that had reported efficacy results from Phase 3 trials of their COVID-19 vaccines. The researchers then pulled all publicly available data on the pharmaceutical companies, focusing on location, conduct and efficacy results of Phase 3 trials.

The database that Sharma and Anand compiled represents the "entire current publicly available global evidence"on the efficacy of approved SARS-CoV-2 vaccines.

Relying on the data, the researchers examined whether there was a connection between the prevalence of COVID-19 infection rates at trial sites and the efficacy of COVID-19 vaccines. Geographic location was found to have a significant association with the observed efficacy of COVID-19 vaccines. Vaccine trials conducted in locations with a low infection rates reported higher efficacy, while trials conducted in locations with high infection rates reported lower efficacy.

The findings have important implications for shaping public policy, patient care and individual choices. Public health organizations advise individuals, organizations, medical professionals, and governmental agencies about the efficacy of vaccines based on the results of clinical trials conducted by pharmaceutical companies. That advice is often the launching point for legislation and/or policies for the public, corporations, schools, medical clinics and governmental oversight.

Most of the advice comes from well-established and respected governmental agencies such as the Centers for Disease Control, Food and Drug Administration and the World Health Organization, which also work in conjunction with pharmaceutical companies that develop and test vaccines.

研究人员认为,疫苗功效可以be validly interpreted only in conjunction with the level of pandemic prevalence, and that Phase 3 trials should include analysis of participant samples of mutant strains, which could lead to breakthrough infection and a high level of the virus.

"When efficacy results of Phase 3 trials are reported, they should include the level of pandemic prevalence at the trial locations," Anand said. "That would provide more meaningful information for policy makers, as compared to the current practice of reporting efficacy results only."

The researchers' study was published inPLOS ONE, a Public Library of Science publication.